Germo Gericke

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 2.

Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 2.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 28, 2025

Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 1.

Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 1.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 15, 2025

Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.

Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 30, 2024

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: June 25, 2021

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Journal: The New England journal of medicine

Published: June 23, 2021

Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers.

Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers.

Journal: Endocrine

Published: May 12, 2021

A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands.

A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 30, 2021

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.

Journal: European journal of nuclear medicine and molecular imaging

Published: November 04, 2019

Showing 1-8 of 8

Last Updated: 09/26/2026